

CURRICULUM VITAE

AARON E. MILLER, M.D.

CURRENT POSITION

March 2004—Present ---Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY 10029

March 2004—Present---Professor of Neurology, Icahn School of Medicine at Mount Sinai

ACADEMIC APPOINTMENTS

Instructor in Neurology; Albert Einstein College of Medicine, Bronx, NY; 1977-78

Assistant Professor of Neurology; Albert Einstein College of Medicine; Bronx, NY 1978-1981

1981--1999: Visiting Assistant Professor of Neurology, Albert Einstein College of Medicine, Bronx, New York

1985--1992: Associate Professor of Clinical Neurology, State University of New York Health Sciences Center at Brooklyn

1992-2003: Professor of Clinical Neurology, State University of New York Health Sciences Center at Brooklyn

2001–2004: Clinical Professor of Neurology, Mt. Sinai School of Medicine, New York, NY

2004—present: Professor of Neurology, Mt. Sinai School of Medicine, (now Icahn School of Medicine at Mount Sinai) New York, NY

HOSPITAL APPOINTMENTS

Attending Neurologist, Bronx Municipal Hospital Center 1978-1999

Attending Neurologist, Albert Einstein College Hospital 1978-1981

Director, Division of Neurology and Attending Neurologist, Maimonides Medical Center, Brooklyn, New York 1981—present

Attending Neurologist, Kings County Hospital Center, 1981-2001

Attending Neurologist, Metropolitan Jewish Geriatric Center 1981--present

Attending Neurologist, Mt. Sinai Hospital (now Icahn School of Medicine at Mount Sinai), New York, 1999—present

8/14/2022

EDUCATION:

B.A., June, 1964, Magna cum laude, with Honors in Psychology
Brandeis University
Waltham, Massachusetts

M.D.,
June, 1968
New York University School of Medicine
New York, New York

POSTDOCTORAL TRAINING:

Internship: July 1, 1968--June 30, 1969
Bronx Municipal Hospital Center
Bronx, New York
Straight Medicine

Junior Assistant Residency July 1, 1969--June 30, 1970
(Medicine): Bronx Municipal Hospital Center
Bronx, New York

Neurology Residency: July 1, 1970--June 30, 1971
July 1, 1973--June 30, 1975
(Chief resident, '74-'75)
Albert Einstein College of Medicine
Bronx, New York

Postdoctoral Fellowship (Neurovirology and immunology):

Department of Epidemiology
Division of Infectious Disease
(Laboratory of Dr. Neal Nathanson)
Johns Hopkins University School of Hygiene and Public Health
Baltimore, MD.
July 1, 1975—June 30, 1977

Department of Microbiology and Immunology
(Laboratory of Dr. Barry Bloom)
Albert Einstein College of Medicine
Bronx, New York
July 1, 1977—June 30, 1978

Recipient of National Multiple Sclerosis Society Fellowship, July 1, 1976--June 30, 1978.

MILITARY SERVICE

Lieutenant Commander

United States Naval Reserve

Active duty obligation fulfilled at St. Albans Naval Hospital, Queens, New York, July, 1971--June, 1973

CERTIFICATION

National Board of Medical Examiners, July 1, 1969

Certification, American Board of Internal Medicine, 1972

Certification in Neurology, American Board of Psychiatry and Neurology, April, 1977.

LICENSURE

Medical License, New York State Dept. of Education, July, 1969—current, #104308

Medical License, Maryland, 1975-77, voluntarily inactive

HONORS/AWARDS/PATENTS

Phi beta kappa, Mu chapter of Massachusetts, Brandeis University, 1964

Alpha omega alpha, New York University School of Medicine, 1968

Teacher-Investigator Award, NINCDS, July, 1979--April, 1981

Fellow, American Academy of Neurology. 1985

Member (elected), American Neurological Association, 1998

OTHER PROFESSIONAL APPOINTMENTS

Councillor, American Society for Neurologic Investigation (1982-1984)

Brooklyn Neurological Society, Vice-president (1986-1988); Secretary/treasurer (1983-1986)

Editorial Board, MS Quarterly (1982--2001)

Editorial Board, MS Indicative Abstracts (1985--1988)

Editorial Board, Multiple Sclerosis Research Reports, Demos Publications (1989--1991)

Co-chairman, Professional Advisory Committee, New York Multiple Sclerosis Society (1988-1991; member from 1983)

National Medical Advisory Committee, National Multiple Sclerosis Society (1988--1991; 1994--present; Chairman 2002--2010)

Council of PAC Chairmen and Clinic Directors, National Multiple Sclerosis Society (1988--1991)

Subcommittee on Foreign Education, American Academy of Neurology (1989--1994)

Chairman, Program Accreditation and Development Subcommittee (formerly known as Regional Education Subcommittee), American Academy of Neurology (1989-1997)

Chairman, Clinical Advisory Committee, New York Multiple Sclerosis Society (1991--2004)

Data and Safety Monitoring Committee, A randomized-double blind placebo-controlled trial of copolymer 1 in relapsing-remitting multiple sclerosis (sponsored by Teva), (1991—1994)

Chairman, Professional Education Committee, National Multiple Sclerosis Society (1993--2002)

President-elect, Consortium of Multiple Sclerosis Centers (1993-- 1994)

Executive Board, Consortium of Multiple Sclerosis Centers (1993--1999)

President, Consortium of Multiple Sclerosis Centers (1994--1995)

Task Force on Clinical Outcomes Assessment, National Multiple Sclerosis Society (1994--1997)

Chairman, Section on Multiple Sclerosis, American Academy of Neurology (1996-1997)

Chairman, End-point committee, A randomized, double-blind placebo-controlled study of Avonex™ (interferon beta 1-a) in the treatment of subjects at high risk for development of multiple sclerosis following the first onset of an isolated demyelinating event. (Biogen, Lawrence Jacobs, PI) (1996-2000)

Member, Annual Meeting Management Committee, American Academy of Neurology (1997—2003)

Chairman, Annual Meeting Subcommittee, American Academy of Neurology (1997-2003)

Co-chairman, Education Committee, American Academy of Neurology (1997-2003)

Member, Research Programs Advisory Committee, National Multiple Sclerosis Society (2003—2020)

Member, Steering Committee, A double-blind, placebo-controlled, parallel group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis. (Biogen, Inc.) (2003—2005)

Member, Board of Directors, National Multiple Sclerosis Society (2003—2017)

Editor, Continuum. American Academy of Neurology (2003—2012). (Continuum is the bimonthly continuing education journal of the AAN)

Member, American Academy of Neurology/American Board of Psychiatry and Neurology Leadership Committee (2003—present)

Member, Publications Committee, American Academy of Neurology (2003—present)

Member, Steering Committee for development of Teriflunomide as treatment for Multiple Sclerosis; Sanofi-Aventis, 2004—2013

Member, Data Monitoring and Safety Committee for Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects with Multiple Sclerosis, Abbott Laboratories, 2006--2008

Member, Data Monitoring and Safety Committee for Study of SB-683699 Compared to Placebo in Subjects with Relapsing-Remitting Multiple Sclerosis, Glaxo Smith Kline, 2007—2012

Chairman, Data Monitoring and Safety Committee for A Study of Safety and Efficacy of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis, ONO, 2009—2013.

Chairman, Data Monitoring and Safety Committee for A 12 Week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients, Daiichi-Sankyo, 2009—2011

Member, Board of Directors, American Academy of Neurology 2009—2013

Secretary, Board of Directors and member of Executive Committee of the Board, American Academy of Neurology, 2013--2017

Chairman, Editors-in-chief Committee, American Academy of Neurology (2009—2011)

Member, Education Committee, World Federation of Neurology, 2010—2012

Member, Scientific Working Group, advising Canadian Institute of Health Research on Chronic Cerebrospinal Venous Insufficiency, 2010--current

Member, Data Monitoring and Safety Committee for Phase 3 trial of ofatumumab in relapsing multiple sclerosis, Glaxo Smith Kline, 2012—2014

Member, Publications Committee, World Federation of Neurology, 2012—2014

Editor, Continuum Audio, a joint venture of Audio Digest and American Academy of Neurology, 2011—present

Section Editor (Therapy), Multiple Sclerosis and Related Disorders, 2011—present

Participant, Advisory Panel on Costs of Medications for Multiple Sclerosis, National Multiple Sclerosis Society, March 2012

Member, Diversity Leadership Work Group, American Academy of Neurology, 2015-2017

Member, Pharmacy Quality Alliance MS Treatment and Monitoring Task Force, 2015-2017

Member, Leadership Committee, American Academy of Neurology, 2017—2021

Member, Fast Forward Board of Managers, National Multiple Sclerosis Society, 2017-present

Member, Publications Committee, American Academy of Neurology, 2011-2021

Chairman, National Medical Advisory Committee, National Multiple Sclerosis Society, 2018—2020

Member, National Medical Advisory Committee, National Multiple Sclerosis Society, 2021—present

Member, Search Committee for Editor of Continuum, American Academy of Neurology, 2021

Member, Scientific Advisory Committee (formerly Research Programs Advisory Committee), National Multiple Sclerosis Society, 2021--current

TEACHING ACTIVITIES

Attending rounds for medical students from Mt. Sinai, SUNY at Brooklyn, and other medical students conducted weekly at Maimonides Medical Center 1981—current (schedule has changed over the years from one month at a time to weekly rounds through the year)

Brain and Behavior, Small Group Leader, Mount Sinai (2nd year course)—2006—current

Attending Rounds, Ward Service, Mount Sinai School of Medicine, 1 month/year; 2004-current

Morning Report for Residents and Students, weekly, Mount Sinai School of Medicine, 2005—current

Supervisor, Multiple Sclerosis Fellows (up to 6); Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine

OTHER ICAHN SCHOOL OF MEDICINE ACTIVITIES

Department of Neurology Representative to Faculty Council, 2010—present

Department of Neurology, Vice-Chair for Education, 2017--present

GRANT SUPPORT

Past Grants (Partial list—information about additional pharmaceutical grants in 1980s not available)

8/14/2022

NINDS Teacher-Investigator Development Award	7/79—4/81 (voluntarily terminated by grantee because of change of position) Paid full salary (exact amount not available)
Forest Laboratories The efficacy of extended-release oral physostigmine in Alzheimer's disease and senile dementia of the Alzheimer's type. Site principal investigator	5/89—6/95 \$257,136
Dupont-Merck A randomized, placebo-controlled study of Dup 996 (linopirdine), 90 and 120 mg daily in patients with mild to moderate dementia of the Alzheimer's type. Site principal investigator	12/91—11/93 \$116,450
Maimonides Research and Development Foundation Botulinum toxin therapy of tremor in multiple sclerosis Principal investigator	1/92—1/93 \$7,500
Glaxo Ondansetron in the study of dementia Site principal investigator	11/92—1/95 \$80,297
Organon Trial of Organon 10172 in acute stroke treatment Site principal investigator	4/93—10/96 \$110,209
AutoImmune, Inc. A double-blind, placebo-controlled, multi-center study of oral myelin (Myloral™) in the treatment of early relapsing-remitting multiple sclerosis. Site principal investigator	7/94—9/97 \$158,439
NINDS Warfarin antiplatelet recurrent stroke study Site principal investigator	10/94—4/99 \$132,827
National Multiple Sclerosis Society A multi-center, randomized, double-blind placebo-controlled trial of influenza immunization in multiple sclerosis Principal Investigator	8/1/95—7/31/96 \$25,000

8/14/2022

Ciba-Geigy Selfotel protocol 07 M8535Q—A multicenter, randomized, double-blind, parallel trial comparing the efficacy and safety of a single IV dose (1.5 mg/kg) of Selfotel with placebo in patients age 40-85 with acute ischemic stroke. Site principal investigator	8/95—4/96 \$24,294
Pharmacia, Inc. Linomide—A randomized, double-blind, placebo-controlled, phase 3 study of roquinimex (Linomide®) in relapsing-remitting and secondary progressive multiple sclerosis Site principal investigator	9/95—6/98 \$210,015
Berlex Phase III, double-masked, placebo-controlled study to evaluate the safety and efficacy of two doses of Betaseron in patients with secondary progressive multiple sclerosis. Site principal investigator	5/96-12/99 \$402,807
Alzheimer's Disease Cooperative Study Group Idebenone—A randomized, double-blind, placebo-controlled twelve-month safety and efficacy trial of 120, 240, and 360 mg tid of idebenone (CV-2619) in patients with probable Alzheimer's disease Site principal investigator	7/97—3/00 \$346,132
Pfizer A global randomized, double-blind study (with open-label extension to evaluate the efficacy and safety of Viagra™ (sildenafil) in multiple sclerosis patients with erectile dysfunction Site principal investigator	1/98—6/99 \$10,290
ICOS Multiple sclerosis multidose protocol AMS05 Site principal investigator	6/98—12/99 \$24,017
Elan Pharmaceuticals Tizanidine MR study, AN021-302 Site principal investigator	2/99—5/00 \$27,939
Alzheimer's Disease Cooperative Study Group A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety	8/99—1/04 \$23,905

8/14/2022

and efficacy of vitamin C and donepezil hydrochloride (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer’s disease.
Site principal investigator

Aentis Pharmaceuticals 12/99—12/03
\$120,432
A multi-national, multi-center, double-blind, placebo controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate for injection in Primary Progressive Multiple Sclerosis patients.
Site principal investigator

Cromedica 3/00—4/01
\$72,874
Multicenter, randomized, double-blind, placebo-controlled study to evaluate Neotrofin™ (AIT-082) in patients with probable Alzheimer’s disease of mild to moderate severity
Site principal investigator

Teva Neuroscience 4/00—4/02
\$189,557
CORAL—A multinational, multicenter randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability, and safety of 2 doses (5 mg and 50 mg) glatiramer acetate orally administered in relapsing-remitting multiple sclerosis.
Site principal investigator

Pfizer 1/01—7/02
\$17,380
A 12-week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in the treatment of cognitive impairment in patients with multiple sclerosis.
Site principal investigator

Serono 2/02—1/03
\$81,098
An open label, randomized, multicenter comparative study of Rebif 44 mcg administered three times per week by subcutaneous injection compared with Avonex 30 mcg administered once per week by intramuscular injection in the treatment of relapsing-remitting multiple sclerosis.
Site principal investigator

Serono 2/02—9/02

8/14/2022

A randomized, multicenter, parallel group, open-label study comparing the tolerability of Rebif injection with and without the use of Rebiject™ Mini in relapsing remitting MS patients. Site principal investigator	\$20,500
Biogen, Inc. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the safety and efficacy of natalizumab, when added to Avonex (Interferon beta-1a), in subjects with relapsing-remitting MS (SENTINEL). Site principal investigator.	4/02—2/05 \$19,000 per pt (7 pts enrolled)
Immunex Prospective open-label tolerability and safety monitoring study of Novantrone (mitoxantrone for injection, concentrate) in a selected cohort of MS patients. Site principal investigator	6/02—12/03 \$2,425
Sanofi-Synthelabo Research Clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA). Site principal investigator.	1/03—05 \$4,025 per patient (5 patients enrolled)
Acorda Therapeutics, Inc. Double-blind, placebo-controlled, 20-week parallel group study to evaluate safety, tolerability, and activity of oral fampridine-SR in subjects with multiple sclerosis. Site principal investigator.	2/03—1/06 \$8,250 per patient (9 patients enrolled)
Biogen A double-blind, randomized, placebo-controlled, parallel group design safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis. Site principal investigator	4/03—2/05 \$12,600 per patient (5 patients enrolled)
NIH/ Immune Tolerance Network (ITN) A randomized, double-blind, placebo-controlled, Multi-center study to evaluate the efficacy and safety Of atorvastatin in patients with clinically isolated Syndrome and high risk conversion to MS (STAYCIS) Site principal investigator	3/04—2/10 \$36,641 per patient

8/14/2022

Acorda Therapeutics Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg BID) in Subjects with Multiple Sclerosis MS-F203 Site sub-investigator	12/04—2/08 \$6,925 per patient
Genentech A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis: U2786g Site principal investigator	6/04—9/09 \$34,823 per patient
Teva Neuroscience A multi-center, randomized, double-blind, placebo controlled study assessing the add-on effect of oral steroids in relapsing remitting multiple sclerosis subjects treated with glatiramer acetate (GA) (ASSERT). Site principal investigator	11/05—3/10 \$21,317 per patient
Acorda Therapeutics, Inc. Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d.) in patients with Multiple Sclerosis MSF204 Site sub-investigator	04/07—1/09 \$8,248 per patient
Novartis A Randomized Placebo-Controlled Trial of Fingolimod in PPMS (INFORMS) Site PI	2008-2014
Biogen A Randomized Placebo-Controlled Trial of Natalizumab on Reducing Disability Progression in SPMS (ASCEND trial) Site PI	2011-2016
Questcor With Acute Relapses Failing IV Methylprednisolone PI	2013-2018
Biogen An Open-Label, Multicenter Study in Subjects with Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On	2010—2012

8/14/2022

Therapy to Beta Interferons (IFN β) or Glatiramer Acetate (GA)
Site principal investigator

Multicenter, Double-blind, Randomized, Parallel-group,
and Safety of Daclizumab High Yield Process (DAC HYP)
versus Avonex[®] (Interferon β -1a) in Patients with
Relapsing-Remitting Multiple Sclerosis
Site sub-investigator 2010-2014

Novartis 2/09—present
\$56,255 per patient
A double-blind, randomized, multi-center, placebo
Controlled, parallel-group study comparing the
orally once daily versus placebo in patients with PPMS
Site principal investigator

Sanofi-Aventis 7/08—closed
\$33,028 per patient
An international, multi-center, randomized, double-blind,
placebo-controlled, parallel group study to evaluate the
efficacy and safety of two year treatment with teriflunomide
7 mg once daily and 14 mg once daily versus placebo in
patients with a first clinical episode suggestive of
multiple sclerosis.
Site sub-investigator

Genzyme 3/08—closed
\$30,489 per patient
A Phase 3, Randomized, Rater- and Dose-Blinded Study
Comparing Two Annual Cycles of Intravenous Low- and
High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous
Interferon Beta-1a (Rebif[®]) in Patients with
Relapsing-Remitting Multiple Sclerosis Who Have Relapsed
On Therapy
Site sub-investigator

Acorda Therapeutics, Inc. 1/08—closed
\$8,248 per patient
Open Label Extension Study to Evaluate the Safety,
Tolerability and Activity of Oral Fampridine-SR in Patients
with Multiple Sclerosis who Participated in the MS-F204 Trial
204 EXT
Site sub-investigator

Novartis 9/06—closed
\$42,937 per patient
A 24 month, double-blind, randomized, double-blind,
Parallel group study comparing efficacy and safety of
FTY7201.25mg and 0.5mg administered orally once daily
versus placebo in patients with RRMS (FREEDOMS II)
Site principal investigator

Acorda Therapeutics, Inc. 11/05—closed

8/14/2022

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis who Participated in the MS-F203 Trial 203 EXT Site sub-investigator	\$6,925 per patient
Acorda Therapeutics, Inc. Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis 202 EXT Site sub-investigator	3/04—closed \$9,112 per patient
National Multiple Sclerosis Society (Fred Lublin, PI) Oral megadose corticosteroid therapy of acute exacerbations of multiple sclerosis (OMEGA). Site principal investigator.	8/1/03--closed \$3,060 per patient (up to \$49,560)
New York State Department of Health and Jacobs Foundation The establishment of a patient registry and initiation of related Projects of the New York State Multiple Sclerosis Consortium. Site principal investigator	7/96--2005

Current Grants

NINDS Mount Sinai Network of Excellence in Neuroscience Trials (NeuroNext) Site Co-Principal Investigator	2018-present \$339,000 1 st year
Johns Hopkins University School of Medicine (PCORI Funded) Traditional vs Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial Site principal investigator	2019—present
Immune Tolerance Network (NIH) A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant For Treatment-Resistant Relapsing Multiple Sclerosis (BEAT-MS) Site Principal investigator	2020--present
University of Colorado (PCORI Funded) Discontinuation of Disease Modifying Therapy (DMT) in Multiple Sclerosis (MS) (DISCO-MS) Site Principal Investigator	2017—Present

8/14/2022

Med Day 2017-present
 Effect of MS1003 in Progressive Multiple Sclerosis:
 A Randomized, Double-Blind, Placebo-Controlled Study
 Site PI

Roche 2015-present
 Randomized Study of Ocrelizumab Compared to Placebo
 For Primary Progressive MS (ORATORIO Extension
 Trial)
 Site PI

\Novartis 2012-present
 A Randomized Placebo-Controlled Trial of Siponimod
 In Secondary Progressive MS (EXPAND trial)
 Site PI (leading North American recruiter)
 Site PI in EXPAND-Extension Trial

PUBLICATIONS

Original peer-reviewed articles

1. **Miller A** and Nathanson N: Rabies: Recent advances in pathogenesis and control. *Annals of Neurol.*, 2: 511-519, 1977.
2. Georgsson G, Petursson G, **Miller A** et al: Experimental visna in fetal Icelandic sheep. *J. Comp. Pathol.* 88: 597-605, 1978.
3. Nathanson N and **Miller A**: Epidemiology of multiple sclerosis: Critique of the evidence for a viral etiology. *Am. J. Epidemiol.*, 104: 451-461, 1978.
4. **Miller A**, Morse HC, III, Winkelstein JA and Nathanson N: The role of antibody in recovery from experimental rabies: 1. Effect of depletion of B and T cells. *J. Immunol.* 121: 321-326, 1978.
5. Nathanson N, Petursson G, Georgsson G, Palsson P, Martin J, and **Miller A**: Pathogenesis of visna IV. Spinal fluid studies. *J. Neurol. Pathol. Exp.* 1979. *Neurol.* 38: 197-208,
6. **Miller A**: Selective decline in cellular immune response to varicella-zoster in the elderly. *Neurology* 30: 582-587, 1980.
7. Neighbour PA, **Miller AE**, and Bloom BR: Interferon responses of leukocytes in

- multiple sclerosis. *Neurology* 31: 561-566, 1981.
8. **Miller AE**, Neighbour PA, Katzman R, Aronson M, and Lipkowitz R: Immunological studies in senile dementia of the Alzheimer type: evidence for enhanced suppressor cell activity. *Annals of Neurol.* 10:506-510, 1981.
 9. Bornstein MB, **Miller A**, Teitelbaum D, et al: Multiple sclerosis: Trials of a synthetic peptide. *Ann. Neurol.* 11:317-319, 1982.
 10. **Miller AE**: Cessation of stuttering with progressive multiple sclerosis. *Neurology* . 35: 1341-1343, 1985
 11. Bornstein MB, **Miller A**, Slagle S. et al: Copolymer 1 in exacerbating-remitting multiple sclerosis. *New England J. Med.* 317:408-414, 1987.
 12. McDowell F, **Miller A**, Namerow N, and Scheinberg L: The symptomatic management of multiple sclerosis. *J. Neurorehab.* 2:137-139, 1988.
 13. Merriam AE, Hegarty A, and **Miller A**: A proposed etiology for psychotic symptoms in white matter dementia. *Neuropsychiatry, neuropsychology and behavioral neurology.* 2:225-228, 1989.
 14. Hegarty A, **Miller A**, and Merriam AE: The mental disabilities of metachromatic leukodystrophy: Implications concerning the differentiation of cortical, subcortical gray, and white matter dementias. *Neuropsychiatry, neuropsychology, and behavioral neurology:* 3: 217-219, 1990.
 15. Ofosu-Appiah W, Mokhtarian F, **Miller A** et al. Characterization of in vivo-activated T cell clones from peripheral blood of multiple sclerosis patients. *Clin immunol and immunopathol* 58: 46-55, 1991.
 16. Hriso E, Masdeu JC, **Miller A**. Monocular elevation weakness and ptosis: An oculomotor fasciculus syndrome? *J. Clin. Neuroophthal.* 11:111-113, 1991.
 17. Bornstein MB, **Miller A**, Slagle S et al. A placebo-controlled, double-blind, randomized, two-center pilot trial of Cop 1 in chronic progressive multiple sclerosis. *Neurology* 41:533-539, 1991.
 18. Shirazian D, Mokhtarian F, Herzlich BC, **Miller AE**, Grob D. Presence of cross-reactive antibodies to HTLV-1 and absence of antigens in patients with multiple sclerosis. *J Lab Clin Med* 122:252-259, 1993.
 19. Keilson MJ, Drexler ED, **Miller AE**, Bruining K. Central pontine myelinolysis with complete recovery. *J Neuroimag* 1994;4:47-48.
 20. Mokhtarian F, Shi Y, Shirazian D, Morgante L, **Miller A**, Grob D. Defective production of anti-inflammatory cytokine, TGF-B by T cell lines of patients with active multiple sclerosis. *J. Immunol.*, 1994, 152:6003-6010.

21. Krupp LB, Coyle PK, Doscher C, **Miller A**, Cross A, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: Results of a double blind randomized parallel trial of amantadine, pemoline, and placebo. *Neurology*, 1995;45:1956-1961.
22. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, **Miller A**, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. *Ann Neurol* 1996;40:469-479.
23. **Miller AE**, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, LaRocca N, Lopez S. A multi-center, randomized, double-blind placebo-controlled trial of influenza immunization in multiple sclerosis. *Neurology* 1997; 48:312-314.
24. Mokhtarian F, Shirazian D, Morgante L, **Miller A**, Grob D, Lichstein E. Influenza virus vaccination of patients with multiple sclerosis. *Multiple sclerosis* 1997;3:243-247.
25. Jacobs LD, Wende KE, Brownschidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, **Miller AE**, Perel A, Smith CR, Snyder DH and the New York State Multiple Sclerosis Consortium. A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium. *Multiple Sclerosis* 1999;5:369-376.
26. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, **Miller AE**, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. *Brain* 1999;122:871-882.
27. Schwid S, Goodman A, Apatoff B, Coyle P, Jacobs L, Krupp L, **Miller A**, Wende K, Brownschidle, and the New York State Multiple Sclerosis Consortium. Are quantitative functional measures more sensitive to worsening MS than traditional measures? *Neurology* 2000;55:1901-1903
28. Cook SD, Quinless JR, Jotkowitz A, Beaton P, and the Neutralizing Antibody Study Group (**Miller A**—member). *Neurology* 2001;57:1080-1084.
29. Pedley TA, Swift TR, **Miller A**, Fahn S. Pharmaceutical industry support of the AAN Annual Meeting. Policies and Violations. *Neurology* 2002;58:519-521.
30. Tullman MJ, Lublin FD, **Miller AE**. Immunotherapy of multiple sclerosis—current practice and future directions. *J Rehabil Res Dev* 2002; 39:273-285
31. Weinstock-Guttman B, Jacobs LD, Brownschidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Grontera AT, Goodman AD, Gottesman MH, Holub HJ, Lava NS, Lenihan M, Lusins J, Mihai C, **Miller AE**, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smirolto J, New York State Multiple Sclerosis Consortium. Multiple sclerosis characteristics

in African American patients in the New York State Multiple Sclerosis Consortium. *Mult Scler* 2003; 9:293-298.

32. Boneschi FM, Rovaris M, Johnson KP, **Miller A**, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. *Mult. Scler.* 2003; 9:349-355.
33. **Miller AE**, Coyle PK. Clinical features of multiple sclerosis. *Continuum* 2004;10:38-73.
34. Panitch H, **Miller A**, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. *Neurology* 2004; 63:1788-1795.
35. **Miller AE**. Glatiramer acetate in the treatment of multiple sclerosis. *Neurol Clin* 2005; 215-231.
36. **Miller A**. Ethical issues in MS clinical trials. *Mult Scler* 2005;11:97-98.
37. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, **Miller A**, Pardo L, Kadosh S, Ladkani D; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. *Ann Neurol* 2007; 61:14-24.
38. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, **Miller AE**, Montaban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. *Neurology* 2008; 70 (13 Pt 2):1134-1140.
39. **Miller A**, Spada V, Beerkircher D, Kreitman RR. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing remitting multiple sclerosis. *Mult Scler* 2008;14:494-499.
40. Goodman AD, Rossman H, Bar-Or A, **Miller A**, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandroock AW, GLANCE Investigators. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.
41. Rudick R, Polman C, Cohen J, Walton M, **Miller A**, Confavreux C, Lublin F, Hutchinson M, O'Connor P, Schwid S, Balcer L, Lynn F, Panzara M, Sandroock A. Assessing disability progression with the Multiple Sclerosis Functional Composite. *Multiple Sclerosis* 2009;15:984-997
42. Straus Farber R, Devilliers L, **Miller A**, Lublin F, Law M, Fatterpekar G, Delman B, Naidich T. Differentiating multiple sclerosis from other causes of demyelination using diffusion weighted imaging of the corpus callosum. *J Magn Reson Imaging* 2009;30:732-736.
43. Asche CV, Singer ME, Jhaveri M, Chung H, **Miller A**. All-cause health care utilization and

costs associated with newly diagnosed multiple sclerosis in the United States. *Journal of Managed Care Pharmacy* 2010; 16 (9): 703-712.

44. Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman A, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, **Miller A**, Munschauer FE 3rd, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J. Rapid disease course in African-Americans with multiple sclerosis. *Neurology* 2010;75:217-223.
45. Lunemann A, Tackenberg B, DeAngelis T, da Silva RB, Messner B, Vanoaica LD, **Miller A**, Apatoff B, Lublin FD, Lunemann J. Impaired IFN- γ production and proliferation of NK cells in multiple sclerosis. *Int Immunol* 2011;23:139-148.
46. **Miller AE**. Multiple sclerosis: where will we be in 2020? *Mt Sinai J Med* 2011;78:268-279.
47. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, **Miller A**, Freedman MS, TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med* 2011;365:1293-1303.
48. **Miller A**. Chronic cerebrospinal venous insufficiency in multiple sclerosis: A medical, sociological, and media controversy (invited editorial). *US Neurology* 2012;7:84-86.
49. **Miller AE**, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. *Current Opinion Neurology* 2012; 25 (Suppl 1):S4-S10.
50. Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson T, **Miller AE**, Benzerdjeb H, Li H, Simonson C, O'Connor P. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. *Neurology* 2012;78:1877-1885..
51. Tornatore C, Phillipps JT, Khan O, **Miller A**, Barnes CJ. Practice patterns of US neurologists in patients with CIS, RRMS or RIS: a consensus study. *Neurology: Clinical Practice*, 2012;2:48-57.
52. Khan O, **Miller A**, Tornatore C, Phillipps JT, Barnes CJ. Practice patterns of US Neurologists in SPMS and PPMS: a consensus study. *Neurology: Clinical Practice*, 2012;2:58-66.
53. Rudick RA, **Miller A**. Multiple sclerosis or multiple possibilities: The continuing problem of misdiagnosis (invited editorial). *Neurology* 2012;78:1904-1906.
54. **Miller AE**, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS; for the Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. *Mult Scler* 2012; 18:1625-1632.
55. Haut SR, Bienen EJ, **Miller A**. Clinical overview of the seizure risk of dalfampridine. *Expert Opin Drug Saf* 2012;4:651-657.

56. Cohen JA, Reingold SC, Polman CH, Wolinsky JS, International Advisory Committee on Clinical Trials in Multiple Sclerosis. *Lancet Neurol* 2012;11:467-476.
57. Wolinsky JS, Narayana PA, Nelson F, Satta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, **Miller A**, Freedman MS for the Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. *Mult Scler* 2013; 19:1310-1319.
58. Pandey KS, Krieger SC, Farrell C, Hannigan C, DeAngelis T, **Miller AE**, Lublin FD. Clinical course in multiple sclerosis patients presenting with a history of progressive disease. *Multiple sclerosis and related disorders*. 2013:
59. **Miller AE**. The best clinical paper on multiple sclerosis in 2012. *Mult Scler* 2013;19 (5): 520-1.
60. O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, **Miller AE**, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. *J Neurol* 2013;260 (10): 2472-80.
61. **Miller AE**, Cohen BA, Krieger SC, Markowitz CE, Mattson DH, Tselentis HN. Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis—performance improvement CME. *Mult Scler* 2014; 20(1): 18-23.
62. Vermersch P, Czonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, **Miller AE**, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomized, controlled phase 3 trial. *Mult Scler* 2014; 20(6): 705-16.
63. Confavreux C, O'Connor P, Comi G, Freedman MS, **Miller AE**, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomized, double-blind, placebo-controlled, phase 3 trials. *Lancet Neurol* 2014; 13(3): 247-56.
64. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AUJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, **Miller AE**, Montalban X, O'Connor PW, Petkau J, Possilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: The 2013 revisions. *Neurology* 2014; 83(3): 278-86.
65. DeAngelis TM, **Miller A**. Diagnosis of multiple sclerosis. *Handb Clin Neurol*. . 2014;122:317-342
66. Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M,

- Calabresi PA, Wu G, **Miller AE**, haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. *Brain* 2014; 137 (pt 8): 2271-86.
67. **Miller AE**, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: Results from the TOWER study. *J Neurol* 2014; 261 (9): 1781-8.
 68. **Miller AE**, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; for the TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol* 2014; S1474-4422(14): 70191-7.
 69. Sand IK, Krieger S, Farrell C, **Miller AE**. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. *Mult Scler* 2014; 20:1654-1657.
 71. **Miller AE**. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis. *Expert Rev Clin Immunol* 2015;11:181-194
 71. **Miller AE**. Teriflunomide: a once daily oral medication for the treatment of relapsing forms of multiple sclerosis. *Clin Ther* 2015 Oct 1; 37(10): 2366-80. PMID 26365096.
 72. Ruggieri S, Petracca M, **Miller A**, Krieger S, Ghassemi R, Bencosme Y, Riley C, Howard J, Lublin F, Inglese M. Association of deep gray matter damage with cortical and spinal cord degeneration in primary progressive multiple sclerosis. *JAMA Neurol* 2015 Dec 1;72(12): 1466-74. PMID: 26457955.
 73. Comi G, Freedman MS, Kappos L, Olsson TP, **Miller AE**, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. *Mult Scler Relat Disord* 2016;5:97-104.
 74. O'Connor P, Comi G, Freedman MS, **Miller AE**, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. *Neurology* 2016;86:920-930.
 75. Marrie RA, **Miller A**, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Fiest K, Reider N, Reingold S, Cohen JA, attendees of the International Workshop on Comorbidity in Multiple Sclerosis. *Neurology* 2016;86:1446-1453.
 76. Marrie RA, **Miller A**, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold S, Cohen JA, attendees of the International Workshop on Comorbidity in multiple Sclerosis in Multiple Sclerosis. *Neurology* 2016;86:1437-1445.
 77. Petracca M, Cordano C, Cellerino M, Button J, Krieger S, Vancea R, Ghassemi R, Farrell C, **Miller A**, Calabresi PA, Lublin F, Inglese M. Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? *Mult Scler* 2016; Mar 18 epub ahead of print.

78. Harel A, Ceccarelli A, Farrell C, Fabian M, Howard J, Riley C, **Miller A**, Lublin F, Inglese M. Phase-sensitive inversion-recovery MRI improves longitudinal cortical lesion detection in progressive MS. *PLoS One* 2016, Mar 22 ecollection
79. Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffrey D, Kapoor R, **Miller A**, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. *Mult Scler* 2016, Mar 22, epub ahead of print
80. Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, **Miller AE**, Pelletier D, Racke MS, Trapp BD, Vartanian T, Waubant E. Relapse in multiple sclerosis: relationship to disability. *Mult Scler Relat Disord* 2016;6:10-20.
81. **Miller AE**. Multiple sclerosis disease-modifying therapy and pregnancy. *Mult Scler* 2016; 22:715-716.
82. Maurer M, Coomi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, **Miller AE**, Dive-Pouletty C, Bozzi S, O'Connor PW. Multiple sclerosis relapses are associated with Increased fatigue and reduced health-related quality of life-A post-hoc analysis of the TEMSO and TOWER studies. *Mult Scler Relat Disord* 2016;7:33-40.
83. **Miller AE**. Switching or discontinuing disease-modifying therapies for multiple sclerosis. *Continuum* 2016;22:851-863.
84. **Miller AE**. Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy—Commentary. *Mult Scler* 2016, Jun 8, epub ahead of print.
85. Zivadinov R, Cookfair DL, Krupp L, **Miller AE**, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B. Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSCSC). *BMC Neurol* 2016;16:102.
86. **Miller AE**, Pelletier D. Multiple sclerosis: Rapid diagnosis or right diagnosis? *Neurology* 2016 July 15, epub ahead of print
87. Tornatore C, Philips JT, Khan O, **Miller AE**, Hughes M. Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices. *Neurol Clin Pract* 2016 Aug; 6(4):329-338.
88. Freedman MS, Montalban X, **Miller AE**, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis, *Mult Scler Relat Disord*. 2016 Nov;10:204-212.
89. Petracca M, Cordano C, Cellerino M, Button J, Krieger S, Vancea R, Ghassemi R, Farrell C, **Miller A**, Calabresi PA, Lublin F, Inglese M. Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? *Multi Scler*. 2017 Jan;23(1):43-50.

90. **Miller AE**. Teriflunomide in multiple sclerosis: An update. *Neurodegener Dis Manag*. 2017 Feb;7(1):9-29.
91. Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, **Miller AE**, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. *Mult Scler* 2017 Mar 1, epub ahead of print
92. Poretto V, Petracca M, Saiote C, Mormina E, Howard J, **Miller A**, Lublin FD, Inglese M. A composite measure to explore visual disability in primary progressive multiple sclerosis. *Mult Scler J Exp Transl Clin* 2017 May 18;3(2).
93. Inglese M, Petracca M, Mormina E, Achiron A, Straus-Farber R, Miron S, Fabian M, Krieger S, **Miller A**, Lublin F, Sormani MP. Cerebellar volume as imaging outcome in progressive multiple sclerosis. *PLoS One* 2017 Apr 24;12(4). Petracca, M., Sumowski, J., Fabian, M.,
94. Petracca M, Sumowski J, Fabian M, **Miller A**, Lublin F, Inglese M. Looking into cognitive impairment in multiple sclerosis. *Eur J Neurol* 2017;25: 192–195. doi:10.1111/ene.13489
95. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, **Miller AE**, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald Criteria. *Lancet Neurol* 2018; 17:162-173.
96. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnolds DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; **EXPAND Clinical Investigators**. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind randomized, phase 3 study. *Lancet* 2018 Nov 17; 392(10160): 2170.
97. Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study. *BMC Neurol*. 2018 May 11;18(1):68.
98. Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A. Effect of interferon beta-1a subcutaneously three times a week on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. *BMC Neurol*. 2018 Sep 14;18(1):143.
99. **Miller AE**, Xu C, Macdonell R, Vucic S, Truffinet P, Benamor M, Thangavelu K, Freedman MS. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. *J Clin Neurosci*. 2019. Jan;59:2229-2231.

100. Cicarelli O, Cohen JA, Reingold SC, weinshenker BG; International Conference on Spinal Involvement and Imaging in **Multiple Sclerosis** and Neuromyelitis Optica Spectrum Disorders. *Lancet Neurol.* 2019 Feb (2): 185-197. Doi: 10.1016/S1474-4422 (18) 30460-5. Review
101. Margoni M, Petracca M, SchiaviS, Fabian M, **Miller A**, Lublin Fred, Inglese M.; Axonal water fraction as marker of white matter injury in primary- progressive multiple sclerosis: a longitudinal study; *Eur J Neurol.* 2019 Aug 26 (8): 1068-1074. Doi: 10.1111/ene. 13937. Epub 2019 Mar 25
102. Bar- Or A, Grove RA, Tolson JM, Derosier FJ, Lopez MC, Kavanagh ST, **Miller AE**. 543Author Response: Subcutaneous of autumumab in patients with relapsing remitting multiple sclerosis: The MIRROR study. *Neurology.* 2019 Mar 12; 92 (11):543
103. Gross RH, Sillau SH, **Miller AE**, Farrell , Krieger SC. The Multiple Sclerosis Severity Score: fluctuations and prognostic ability in a longitudinal cohort of patients with MS. *Mult Scler J Exp Transl Clin.* 2019 Mar 18; 5(1): 2055217319837254. doi: 10.1177/2055217319837254. eCollection 2019 Jan-Mar.
104. Klineova S, Brandstadter R, Fabian MT, sand IK, Krieger S, Leavitt VM, Lewis C, Riley CS, Lublin FD, **Miller AE**, Sumowski JF. Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis. *Mult Scler.* 2019 Jun 7:1352458519852725. Doi: 1177/1352458519852725.
105. Comi G, **Miller AE**, Benamor M, Truffinet P, Poole EM, Freedman MS. Characterizing lymphocyte counts and infection rates with long- term teriflunomide treatment: Pooled analysis of clinical trials. *Mult Scher.* 2019 Jun &: 1352458519851981. Doi 10. 1177/1352458519852725
106. Leavitt VM, Brandstadter R, Fabian M, Katz Sand I, Klineova S, Krieger S, Lewis C, Lublin FD, **Miller A**, pelle G, Buyukturkoglu K, De Jager PL, Li P, Riley CS, Tsapanou A, Sumowski JF. Dissociable cognitive patterns relate to depression and anxiety in multiple sclerosis. *Mult Scher.* 2019 Jun 24:1352458519860319.
107. **Miller AE**, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, BenamorM, Purvis A, Wolinsky JS; TOPIC study group. Long Term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. *Mult Scher Realt Disord.* 2019 Aug;33:131-138
108. Katz Sand I, Benn EKT, Fabian M,, Fitzgerald KC, Digga E, Deshpande R, **Miller A**, Gallo S, Arab I. Randomized- controlled trial of a modified Mediterranean dietary program for multiple sclerosis: A pilot study. *Mult Scher Relat Disord.* 2019 Nov;36:101403
109. Brandstadter R, Fabian M, Leavitt VM, Krieger S, Yeshokumar A, Katz Sand I, Klineova S, riley CS, Lewis C, Pelle G, Lublin F, **Miller AE**, Sumowski JF. Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis. *Mult Scher.* 2019 Nov 19:1352458519881760.
110. Brandstadter R, Ayeni O, Krieger SC, Harel NY, Escalon MX, Katz sand I, Leavitt VM, Fabian MT, Buyukturkoglu K, Klineova S, Riley CS, Lublin FD, **Miller AE**, Sumowski JF.

Detection of subtle gait disturbance and future fall risk in early multiple sclerosis. Neurology. 2020 Feb 26. Pii: 10.1212/WNL.00000000000008938.

111. Klineova S, Brandstadter R, Fabian MT, Sand IK, Krieger S, Leavitt VM, Lewis C, Riley CS, Lublin F, **Miller AE**, Sumowski JF. Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis. Mult Scler 2020 (Aug) 26:1111-1120.

112. Comi G, **Miller AE**, Benamor M, Truffinet P, Poole EM, Freedman MS. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. Mult Scler 2020 (Aug);26:1083-1092.

113. Leavitt VM, Brandstadter R, Fabian M, Katz Sand I, Klineova S, Krieger S, Lewis C, Lublin F, **Miller A**, Pelle G, Buyukturkoglu K, De Jager PL, Li P, Riley CS, Tsapanou A, Sumowski JF. Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. Mult Scler 2020; (Sep) 26: 1247-1255.

114. **Miller AE**, Olsson TP, Wolinsky JS, Comi G, Kappos L, Hu X, Xu X, Lublin AL, Truffinet P, Chavin J, Delhay JL, Benamor M, Purvis A, Freedman MS, TOWER investigators. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. Mult. Scler Relat Disord 2020 (Nov) ;46:102435

115. Brandstadter R, Fabian M, Leavitt VM, Krieger S, Yeshokumar A, Katz Sand, Klineova S, Riley CS, Lewis C, Pelle G, Lublin FD, **Miller AE**, Sumowski JF. Mult Scler 2020 (Nov) 26:175201764.

116. Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD, **SPI2 investigative teams**. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2020 (Dec) 19:988-997.

117. **Miller AE**, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R, National Medical Advisory Committee of the National Multiple Sclerosis Society. JAMA Neurol 2021 (Feb) 78:241-246.

118. Glukhovskiy L, Brandstadter R, Leavitt VM, Krieger S, Buyukturkoglu K, Fabian M, Sand IK, Klineova S, Riley CS, Lublin FD, **Miller AE**, Sumowski JF. Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. Mult Scler 2021 (April) 27:568-578.

119. Zhang Y, Staker E, Cutter G, Krieger S, **Miller AE**. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study. Mult Scler Relat Disord 2021 (May) 50:102856.

120. Sumowski JF, Horng S, Brandstadter R, Krieger S, Leavitt VM, Katz Sand I, Fabian M, Klineova S, Graney R, Riley CS, Lublin FD, **Miller AE**, Varga AW. Sleep disturbance and memory dysfunction in early multiple sclerosis. Ann Clin Transl Neurol 2021 (Jun) 8:1172-1182.

121. Glukhovsky L, Kurz D, Brandstadter R, Leavitt VM, Krieger S, Fabian M, Katz Sand I, Klineova S, Riley CS, Lublin FD, **Miller AE**, Sumowski JF. Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments. *Mult Scler* 2021; 27 (July):1277-1283.
122. Satyanarayan S, Safi N, Sorets T, Filomena S, Zhang Y, Fabian M, Horng S, Tankou S, **Miller A**, Krieger S, Lublin F, Sumowski J, Katz Sand I. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. *Mult Scler Relat Disord* 2021 (Mar); 12; 62:103737
123. Glukhovsky L, Brandstadter R, Leavitt VM, Krieger S, Buyukturkoglu K, Fabian M, Sand IK, Klineova S, Riley CS, Lublin FD, **Miller AE**, Sumowski JF. Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. *Mult Scler* 2021 (April) 27:568-578.
124. Katz Sand IB, Fitzgerald KC, Gu Y, Brandstadter R, Riley CS, Buyukturkoglu K, Leavitt VM, Krieger S, **Miller A**, Lublin F, Klineova S, Fabian M, Sumowski JF. *Mult Scler Relat Disord* 2021; 19 (Aug) :53 103031.
125. **Miller AE**. Updates: Review of teriflunomide's use in multiple sclerosis. *Neurodegen Dis Manag* 2021 (Oct; 11:387-408.
126. Wynn D, Goldstick L, Bauer W, Zhao E, Tarau E, Cohen JA, Robertson D, **Miller A**. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotrophin injection for multiple sclerosis relapses that do not adequately respond to corticosteroids. *CNS Neurosci Ther* 2022; 28(Mar):364-371.
127. Sprenger T, Kappos L, Sormani MP, **Miller AE**, Poole EM, Cavalier S, Wuerfl J. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post-hoc analysis of the Temso core and extension studies. *Mult Scler* 2022 ; 29 (April) 13524585221089534 online ahead of print.

Case Reports

1. Nathanson N, Miller A, Martin J and Fischman H: Multiple sclerosis, canine distemper, and measles immunization. *Lancet* 1: 1204, 1978 (letter).
2. Miller A: Immunosuppression for multiple sclerosis. *New England J. Med.* 309:240, 1983 (letter).
3. Drexler ED, Miller A, and Keilson MJ: Left-handedness in dementia. *Neurology* 34:1622, 1984 (letter).

Invited Contributions

1. Bornstein MB, Miller A, Slagle S. et al: Clinical experience with COP 1 in multiple sclerosis. *Neurology* 38 (Suppl. 2): 66-68, 1988.
2. Weiss W, Bornstein MB, Miller A, and Slagle S: Clinical trial design in multiple sclerosis. *Neurology* 38 (Suppl. 2): 80-81, 1988.
3. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving Interferon beta-1b for multiple sclerosis: Report of a consensus conference. *Neurology*. 1996;46:12-18.
4. Miller A. Current and investigational therapies used to alter the course of disease in multiple sclerosis. *Southern Medical Journal* 1997;90:367-378.
5. Miller A. Diagnosis of multiple sclerosis. *Seminars in Neurology* 1998;18:309-316.
6. Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin FD, Paty DW, Rice GP, Weinstock-Guttman B. Multiple Sclerosis. *Continuum* 1999;5:1-196.
7. Pedley TA, Swift TR, Miller A, Fahn S. Pharmaceutical industry support of the AAN annual meeting: policies and vilation. *Neurology* 2002;58:519-521.
8. Miller AE, Rhoades RW. Treatment of relapsing remitting multiple sclerosis: current approaches and unmet needs. *Current Opin Neurol* 2012; 25: S4-S10.
9. **Miller AE**, Calabresi PA. Central vein sign in multiple sclerosis; Ready for front and center? *Neurology* 2018; Apr 30;90(14):631-632.

Books and Book Chapters

1. Nathanson N, Miller A, and Martin J: Epidemiology of multiple sclerosis: Is it consistent with a viral etiology? In Levy N. (ed.): *Multiple sclerosis*, M. Dekker, Publ., New York, 1979
2. Miller A and Scheinberg L: Diseases of central myelin (other than multiple sclerosis). In Conn HF and Conn RB (eds.): *Current Diagnosis* 6, W.B. Saunders Co., Philadelphia, 1980, pp 934-942.
3. Scheinberg L and Miller A: Multiple sclerosis. In Conn HF and Conn RB (eds.): *Current Therapy* 1981, W.B. Saunders Co., Philadelphia, pp 799-803.
4. Nathanson N and Miller A: Rabies, arbovirus encephalitis, postinfectious encephalomyelitis, and Guillain-Barre syndrome. In Nahmias AJ and O'Reilly T (eds.): *Immunology and human infections*, Plenum Publ., New York, 1982, pp 243-272.

5. Bornstein MB, Miller A, Slagle S. et al: Clinical trials of copolymer 1 in multiple sclerosis. In Scheinberg L and Raine CS (eds.): Multiple sclerosis: Experimental and clinical aspects. Annals of the New York Academy of Sciences. 436: 366-372, 1984.
6. Bornstein MB, Miller A, Slagle S. et al: Clinical trials of a synthetic polypeptide (copolymer 1) for the treatment of multiple sclerosis. In Gonsette RE and Delmotte P (eds.): Immunological and clinical aspects of multiple sclerosis. MTP Press Ltd., Lancaster, 1984.
7. Miller A: Neurological tumors. In Khafif R, Rafla S and Kopel S (eds). Management of the cancer patient: Current guidelines. Academic Press. New York. 1986.
8. Miller, AE: Clinical features. In Cook SD (ed.), Handbook of Multiple Sclerosis. Marcel-Dekker, Inc., New York, 1990.
9. Miller AE: Multiple sclerosis. In Feldmann E. (ed.). Current Diagnosis in Neurologic Disease. B.C. Decker Inc., Philadelphia, 1994.
10. Miller AE: Sexual dysfunction in multiple sclerosis. In Singer C and Weiner W (eds.). Sexual Dysfunction in Neurologic Disease. Futura. Mt. Kisco, New York, 1994.
11. Miller, AE: Clinical features. In Cook SD (ed.), Handbook of Multiple Sclerosis. Second Edition, Revised and Expanded. Marcel-Dekker, Inc., New York, 1996.
12. Miller AE and Herndon RM. Treatment issues. In Kalb RC(ed). Multiple Sclerosis: The questions you have. The answers you need. Demos Vermande New York, 1996.
13. Miller AE. Multiple sclerosis. In Bogousslavsky J and Fisher M (Eds.) Textbook of Neurology. Butterworth-Heinemann Boston 1998.
14. Miller AE. Case studies. In van den Noort S and Holland NJ. Multiple sclerosis in Clinical PB
15. Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin FD, Paty DW, Rice GP, Weinstock-Guttman B. Multiple Sclerosis. Continuum 1999;5;1-196.
16. Miller AE and Herndon RM. Treatment Issues. In Kalb RC. Multiple Sclerosis. The questions you have—the answers you need. Second edition. Demos Medical Publishing, Inc. New York. 2000.
17. Miller A. Paroxysmal Disorders. In Burks JS and Johnson KP. Multiple Sclerosis. Diagnosis, Medical Management and Rehabilitation. Demos Medical Publishing, Inc. New York. 2000.
18. Miller A. Clinical Features. In Cook SD. Handbook of Multiple Sclerosis. Third Edition. Marcel Dekker, Inc. New York. 2002.

19. Miller AE, Lublin FD, Coyle PK. Multiple Sclerosis in Clinical Practice. Martin Dunitz. London. 2003.
20. Miller AE. Clinical Features. In Cook SD. Handbook of Multiple Sclerosis. Fourth Edition. Taylor and Francis. New York, 2005.
21. Miller A. Ethical consideration in multiple sclerosis clinical trials. In Cohen JA, Rudick RA. Multiple Sclerosis Therapeutics. Third Edition. Informa UK Ltd, 2007.
22. El-Moslimany H, Miller A. Escape therapies and management of multiple sclerosis. In Raine C, McFarland H, Hohlfeld R. Multiple Sclerosis: A Comprehensive Text. Saunders Elsevier. Edinburgh. 2008.
23. Krieger S, Oynhausen S, Miller A. Issues in the design and interpretation of multiple sclerosis clinical trials. In Geisser BS. Primer on Multiple Sclerosis. Oxford University Press, New York 2011.
24. Miller AE, Gligorov N, Krieger SC. Ethical considerations in multiple sclerosis clinical trials. In Cohen JA and Rudick RA. Multiple Sclerosis Therapeutics, Fourth Edition. Cambridge University Press, Cambridge 2011.
25. Miller A. Considering options for managing relapses and disease course. In Kalb RC. Multiple Sclerosis: The Questions You Have, The Answers You Need., Fifth Edition. Demos Health, New York, 2012.
26. Miller AE, DeAngelis TM. Neuroimmunology. Oxford University Press, New York, 2012.
27. Miller A. Suspected spinal cord dysfunction. In Sealfon SC, Stacy CB, Motiwala R. Mount Sinai Expert Guides. Neurology. Wiley Blackwell, West Sussex, UK. 2016
28. Straus-Farber R, Miller A. Assessment and Diagnosis of Relapsing Multiple Sclerosis. In Miller A (ed). Handbook of Relapsing-Remitting Multiple Sclerosis. Springer International Publishing, Switzerland, 2017, pp.41-66.
29. Miller A (ed). Handbook of Relapsing-Remitting Multiple Sclerosis. Springer International Publishing, Switzerland, 2017.
30. Miller AE, DeAngelis T, Fabian M, Katz Sand I (eds

INVITED LECTURES (Recent List)

Course director and speaker, Multiple Sclerosis (Quintessentials), American Academy of Neurology Annual Meeting, Toronto, Canada, April 2010

Treatment of Multiple Sclerosis, in Course “Therapy in Neurology”, American Academy of Neurology Annual Meeting, Toronto, Canada, April 2010

Course Director, Update in Neurology, American Academy of Neurology Fall Conference, Las Vegas, NV, October 2010

Multiple Sclerosis: 2020 Vision—Where Will We Be in 2020; Weill Cornell New York Presbyterian Hospital Monthly Multiple Sclerosis Research Symposia, New York, NY, Sept. 2010

Future Therapy of Multiple Sclerosis Course “Update on Multiple Sclerosis; American Academy of Neurology Fall Conference, Las Vegas, NV, October 2010

Visiting Professor of Neurologic Education, University of Rochester Department of Neurology, Rochester, NY, December 2010

Multiple Sclerosis: 2020 Vision—Where Will We Be in 2020; Grand Rounds, University of Rochester Department of Neurology, Rochester, NY December 2010

Multiple Sclerosis: 2020 Vision—Where Will We Be in 2020; Grand Rounds, Department of Neurology, New York University School of Medicine, New York, NY, February 2011

Course director and speaker, Multiple Sclerosis (Quintessentials), American Academy of Neurology Annual Meeting, Honolulu, HA, April 2011

Treatment of Multiple Sclerosis, in Course “Therapy in Neurology”, American Academy of Neurology Annual Meeting, Honolulu, HA, April 2011

Update on Multiple Sclerosis, in Course: “Update in Neurology”, American Academy of Neurology Annual Meeting, Honolulu, HA, April 2011

Multiple Sclerosis in Course: “Continuum: Test Your Knowledge: American Academy of Neurology Annual Meeting, Honolulu, HA, April 2011

Keynote Public Address: *State of the Science in Therapeutics for Multiple Sclerosis*; International workshop “Diagnosing and Understanding Cognitive Dysfunction in Multiple Sclerosis,” New York Academy of Science, New York, NY, June 2011

Meet the Professors: a case-based approach to diagnosis and treatment of multiple sclerosis; Course Director and Speaker, Fifth Joint Triennial CongressECTRIMS/ACTRIMS, Amsterdam, Netherlands, October 2011

New Media and Communications with Patients: CCSVI as a Case Study; Invited Lecture in “Hot Topics 4”; Fifth Joint Triennial CongressECTRIMS/ACTRIMS, Amsterdam, Netherlands, October 2011

Course Director and Speaker, Multiple Sclerosis Essentials, American Academy of Neurology Annual Meeting, New Orleans, LA, April 2011

Update on Multiple Sclerosis, in Course, “Update in Neurology”, American Academy of Neurology Annual Meeting, New Orleans, LA, April 2011

Speaker, Brain Fair, American Academy of Neurology Annual Meeting, New Orleans, LA, April 2011

Treatment of Multiple Sclerosis, in Course, “Therapy in Neurology”, American Academy of Neurology, Annual Meeting, New Orleans, LA, April 2012

Essentials of Multiple Sclerosis—an interactive communication, 6th International Multiple Sclerosis Conference, Dubrovnik, Croatia, May 2012.

Therapy of Multiple Sclerosis: Past, Present and Future. Grand Rounds, Beth Israel Medical Center (now Mount Sinai Beth Israel), Feb 2015.

Course Director, Continuum Test Your Knowledge. American Academy of Neurology, Annual Meeting, Washington, DC, April 2015.

New and Emerging Disease-Modifying Therapies: A Clinical Overview. Presented in the Symposium: Customizing Disease-Modifying Therapies in an Era of Multiple Drug Delivery Modalities and Mechanisms of Action: How Can We Optimize Treatment Selection Based on Disease Activity, at the Consortium of MS Centers (CMSC) Annual Meeting, Indianapolis, IN, May 2015.

Director and Speaker in Symposium, Practical Strategies for Improving Outcomes in Diverse Populations with MS. Director, at the Consortium of MS Centers (CMSC) Annual Meeting, Indianapolis, IN, May 2015.

Course Director and Faculty Member, Controversies in MS Management,ECTRIMS Congress, Barcelona, Spain, Oct. 2015.

Course Director, Continuum Test Your Knowledge. American Academy of Neurology (AAN), Annual Meeting. Vancouver, BC, Canada, April 2016.

Faculty Presenter, MS Essentials, American Academy of Neurology (AAN), Annual Meeting. Vancouver, BC, Canada, April 2016.

Clinical Application of Disease-Modifying Therapies, Master MS Fellowship Course, Washington, DC, 2016.

Symposium Director and Speaker, Patient-Centric Methods for Overcoming Barriers and Achieving Improved Patient Outcomes in African American and Hispanics with MS, at the Consortium for MS Centers (CMSC) Annual Meeting, Washington, DC, May 2016.

Addressing Challenging Cases in the DMD Management of MS, Annual Meeting of the Kentucky State Neurological Society, Louisville, KY, May 2016.

Hot Topics: CSF Biomarkers Can Predict the Course of MS and the Response to Treatment Against,ECTRIMS Congress, London, UK, September 2016.

Course Director and Faculty Member, Controversies in MS Management,ECTRIMS Congress, London, UK, September 2016.

Expanding DMD Treatment Options for Patients with MS, Annual Meeting of the Pennsylvania State Neurological Society, Bethlehem, PA, Oct 2016.

Expanding DMD Treatment Options for Patients with MS, Annual Meeting of New York Neurological Society, New York, NY, Nov 2016.

Therapy of Multiple Sclerosis: Past, Present, and Future: University of Texas McGovern School of Medicine, Houston, TX, March 2017

Faculty Presenter, MS Essentials, American Academy of Neurology (AAN), Annual Meeting, Boston, MA April 2017.

Curbside Consults program, American Academy of Neurology Annual Meeting, Boston, MA, April 2017

Presenter, Head Talks program on MS, American Academy of Neurology Annual Meeting, Boston, MA, April 2017

Clinical Application of Disease-Modifying Therapies, Master MS Fellowship Course, New Orleans, May 2017.

Course Director and Faculty Member, Controversies in MS Management,ECTRIMS Congress, Paris, FR, October 2017.

Faculty, Advanced Curriculum for Multiple Sclerosis in conjunction with ACTRIMS Forum, San Diego, CA, February 2019

Course Director and Faculty Member, MS in the Trenches, American Academy of Neurology Annual Meeting, Philadelphia, PA, May 2019

Course Director and Faculty Member, Continuum: Test Your Knowledge, American Academy of Neurology Annual Meeting, Philadelphia, PA, May 2019

Faculty, MS Master Fellowship Program; Seattle, WA May 2019

Scientific Highlights, 35th Congress of European Committee on Research and Treatment in MS (ECTRIMS), Stockholm, Sweden, September 2019

Faculty Member, Multiple Sclerosis in Neurology Update, American Academy of Neurology Fall Conference, Las Vegas, NV, October 2019

Course Director and Faculty Member, MS in the Trenches, American Academy of Neurology Fall Conference, Las Vegas, NV, October 2019

Course Director and Faculty Member, Continuum: Test Your Knowledge, American Academy of Neurology Fall Conference, Las Vegas, NV, October 2019

